GATT Technologies is a medical device company that has developed a breakthrough patented synthetic technology to address severe and problematic surgical bleedings and organ leakages.
Gatt Technologies' hemostats and sealants focus on controlling severe surgical bleedings as well as preventing and treating organ leakages.
Gatt Technologies was founded in 2011 by Johan Bender. The company is headquartered in Nijmegen, Gelderland, Netherlands.
Gatt Technologies, by leveraging its patented technology the company has developed a synthetic surgical and sealant platform with the potential to become a superior alternative to the current fibrin and PEG-polymer based solutions in terms of speed, efficacy and cost.
Gatt Technologies is focusing on moving the GATT-Patch, a fast hemostatic sealing patch to be used in general surgery, into clinical trials in Europe and the United States. Additionally, it is further developing its other pipeline products including GATT-Powder (hemostat, laparoscopic use) and GATT-Tape (intestinal anastomotic leakage) and is assessing other potential applications based on its activated polyoxazoline technology such as bone regeneration, anti-adhesion, vascular, and ophthalmology.
Gatt Technologies has raised €10.5M ($11.4M) in a Series B round on May 18, 2020. The financing was led by NGI LLC, along with the participation of Johnson & Johnson Innovation – JJDC, Inc., and Oost NL.